MDM2 and cancer: Since p53β/γ isoforms contribute to NMD inhibition-induced p53 pathway activation and are less susceptible to MDM2-mediated degradation than p53α, NMD inhibition may particularly benefit cancers that are caused by MDM2-mediated degradation of WT p53 (Fig. 9C).